|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] Slovenia is one of the more advanced markets in the Central and Eastern European (CEE) region. Its long-term prospects are, however, hampered by a small population size (only around 2mn), its maturity, and certain shortcomings of its intellectual property (IP) regime pertaining to pharmaceuticals. On a positive note, the relatively wealthy population, high healthcare standards and high prices of branded generics will continue to provide support for a steady growth over the coming years. In addition, the country is required to align its market authorisation dossiers to European Union (EU) standards by the end of 2007, as required by the membership. Prescription drugs will continue to account for the majority of the market by value, which are – at 90% of the total – higher than in other CEE countries. The situation is partly the result of over-prescribing and overuse of hospitals, although the need for healthcare and pharmaceutical cost containment will over time lead to the reduction in the share of prescription drugs, providing impetus for over-the-counter (OTC) market growth. On the other hand, the long tradition of generic pharmaceutical manufacturing, disadvantages facing foreign manufacturers and the high percentage of generics (many of which are highpriced branded generics) as a share of the total market (estimated at 33% in 2007) will continue to stimulate the growth in the generics sector. In BMI's adjusted Business Environment Rankings, Slovenia occupies a position in the middle of the table which compares the 15 key regional markets in Central and Eastern Europe (CEE). Slovenia is tied with Russia in sixth place, just ahead of Romania. While the market size remains a major obstacle to future growth, on a positive side, the expansive private insurance coverage and established trade regimes with Western Europe (boosted by the recent entry into the eurozone) allow for good placement of novel drugs onto the market. The bulk of Slovenia's domestic production, which has traditionally been dominated by Krka and Lek, is destined for export, given the small size of the home market. Domestic consumption is a fairly even mix of imported drugs and locally manufactured generics. Most major multinationals are present on the Slovenian market, although very few have a manufacturing presence, largely as a result of the country's inadequate IP laws, its small size and its proximity to Western Europe. The major exception is Novartis, with its generics subsidiary Sandoz present in Slovenia since its acquisition of Lek in late 2002. |
||||||||||||||||
|
||||||||||||||||
Contents[TOP] Chapter 1 - Executive SummarySlovenia Pharmaceuticals & Healthcare Industry SWOT Slovenia Political SWOT Slovenia Economic SWOT Slovenia Business Environment SWOT Chapter 2 - Slovenia: Business Environment RankingTable: Central And Eastern Europe Pharmaceutical Business Environment Ranking Business Environment Ranking Economics - Long-Term Risk Politics - Long-Term Risk Regulatory Barriers Domestic Sector Threat Market Growth Potential Market Size Ranking Chapter 3 - Slovenia: Market SummaryChapter 4 - Regulatory RegimeIntellectual Property Regime IP Deficiencies Patent Disputes Pricing System Reimbursement Policies Eurozone Entry Chapter 5 - Industry DevelopmentsHealthcare Sector Health Profile Table: Leading Causes Of Death In Slovenia Healthcare Insurance Healthcare Expenditure Pharmaceutical Industry Recent Industry Developments Chapter 6 - Industry Forecast ScenarioOverall Market Forecast Table: Drug Market Indicators Key Growth Factors - Industry Table: Health Expenditure Indicators Key Growth Factors - Macroeconomic Table: GDP, Population & Output Prescription Market Forecast Table: Prescription Drug Market Indicators Table: OTC Market Indicators Generics & Branded Markets Forecast Table: Slovenia Generics And Branded Market Indicators Export/Import Forecasts Table: Table: Export/Import Indicators Other Healthcare Data Forecasts Table: Socio-Demographic Indicators Key Risks To BMI's Forecast Scenario Chapter 7 - Competitive LandscapeChapter 8 - Multinational Company ProfilesPfizer GlaxoSmithKline Novartis Sanofi-Aventis Merck & Co Chapter 9 - Indigenous Company ProfilesKrka Chapter 10 - LekChapter 11 - BMI Forecast ModellingHow We Generate Our Industry Forecasts Pharmaceutical Industry Sources
|
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.
|
||||||||||||||||
Network of European Pharmaceutical & Healthcare Sources[TOP] BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||